Prostate Cancer Clinical Trial
Verified date | September 2017 |
Source | Panacela Labs LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A Phase Ib2, multicenter, randomized, double-blind, placebo-controlled safety and efficacy study evaluating different regimens of the immunotherapeutic drug, Mobilan (M-VM3), in patients with prostate cancer.
Status | Active, not recruiting |
Enrollment | 24 |
Est. completion date | January 2018 |
Est. primary completion date | January 2018 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 45 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Subscribed Informed consent for participation in the trial 2. Men aged 45 to 75 years 3. Patients with histologically verified prostate cancer, stage ?1-?3, N0, M0 4. Patient's ECOG status 0-2 5. Negative tests for serologic markers of HIV-infection, viral hepatitis ? and ?, syphilis 6. Patient and his partner should agree to use barrier contraception throughout the study period Exclusion Criteria: 1. Failure to obtain Informed consent 2. Clinical or radiological signs of metastases 3. Indication to hormone therapy of prostate cancer 4. Clinically significant cardiovascular diseases: - Myocardial infarction within 6 months prior the screening - Unstable stenocardia within 3 months prior the screening - Severe circulation failure (FC III) - Clinically significant arrhythmias - Hypotension (systolic blood pressure < 86 mm Hg) or bradycardia with HR < 50 beats per min. - Uncontrolled arterial hypertension (systolic blood pressure > 170 mm Hg or diastolic blood pressure > 105 mm Hg.) 5. Clinically significant CNS diseases at the screening 6. Current infection or another severe or systemic disease which increases risk of treatment sequel 7. Pituitary gland or adrenal disorders in medical history 8. Other malignant tumors within the last 5 years 9. Other concomitant diseases in medical history which according to Investigator may aggravate during the study, including uncontrolled diabetes mellitus, rectal diseases, rectal fissures, hemorrhoid, rectal polyps, rectostenosis, inflammatory urinary diseases: chronic prostatitis, cystitis, urethral catheter, chronic urine retention. 10. Complicated allergic history, systemic allergic reaction, any dietary allergy, intolerability, limitations or specific diets which according to the Investigator may be a contraindication for subject participation in the present study. 11. Administration of drug products which have a marked effect on immune system within 3 previous months prior the screening, long-term intake of disaggregants (warfarin, low molecular heparin except for ThromboASS). 12. Participation in other clinical studies or administration of investigational drug products within 30 days prior the screening, or persisting adverse reactions of any investigational drug product. 13. Any clinically significant patient's health disorders and/or laboratory abnormalities not enlisted in the Protocol which are identified at the screening, and/or any reason which according to the Investigator may prevent the patient's participation in the study. 14. Drug or alcohol abuse at the screening or in the past which according to the Investigator makes the patient ineligible for participation in the study. 15. Vaccination made 14 days prior the study 16. Unability to understand or follow study instructions 17. Lack of availability during 6 months after administration of the investigational drug product, fails to follow visit schedule 19. Individual intolerability of the investigational drug product components Study withdrawal criteria: 1. Any patient may refuse from the study participation on his own wish in any moment on any study stage. 2. Principal Investigator may withdraw any patient from the study in the following cases: - Investigator makes the decision that a patient should be withdrawn in his own best interests - Patient develops any serious adverse reactions/events in the screening period - Patient has been enrolled to the study with violations, or does not follow the protocol requirements - Patient needs additional treatment in the screening period 3. Sponsor has right to terminate the study in any moment. 4. Regulatory authorities have right to terminate the study in any moment. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Moscow State Budgetary Healthcare Institution "City Clinical Hospital ? 57" of Moscow Healthcare Department | Moscow | |
Russian Federation | Moscow State University of Medicine and Dentistry | Moscow | |
Russian Federation | Federal State Budgetary Institution "Saint Petersburg Clinical Scientific and Practical Center for Special types of medical care (Oncological)" | Saint Petersburg | |
Russian Federation | Federal State Budgetary Institution "Scientific Research Oncology Institute named after N.N. Petrov" of the Ministry of Health of the Russian Federation | Saint Petersburg |
Lead Sponsor | Collaborator |
---|---|
Panacela Labs LLC |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Frequency and intensity of adverse events (according to CTCAE v 4.03 classification) | Baseline to up to 45 days after the first drug administration | ||
Primary | Counting of CD4+ and CD8+ cells in prostate biopsy and surgery samples | Using immunological assays | Baseline to up to 45 days after the first drug administration | |
Secondary | Change in total Prostate-specific antigen (PSA) level | Baseline to up to 45 days after the first drug administration | ||
Secondary | Value of the Irani score of post-operative prostate tissue (if material is available for analysis) | Irani J (1997) scale include histological assessment of slide mounts obtained after operation as follow: Degree of immune cell infiltration: 0 - No inflammatory cells, 1 - Scattered inflammatory cell infiltrate within the stroma without lymphoid nodules, 2 - Nonconfluent lymphoid nodules, 3 - Large inflammatory areas with confluence of infiltrate |
On Day 30 after the first drug administration | |
Secondary | Value of the Gleason score of post-operative prostate tissue (if material is available for analysis) | The Gleason grading system is used to evaluate the stage of prostate cancer using samples from biopsy or post- surgical samples as follow: 1 - The cancerous prostate closely resembles normal prostate tissue. 2 - The tissue still has well-formed glands, but they are larger and have more tissue between them. 3 - The tissue still has recognizable glands, but the cells are darker. 4 - The tissue has few recognizable glands. 5 - The tissue does not have any or only a few recognizable glands. |
On Day 30 after the first drug administration | |
Secondary | Plasma concentration of inflammatory cytokines | Baseline to up to 45 days after the first drug administration | ||
Secondary | Presence of protein 502s in blood plasma | Using ELISA assay | Baseline to up to 45 days after the first drug administration | |
Secondary | Presence of protein 502s in prostate biopsy and surgery samples | Using ELISA assay | Baseline to up to 45 days after the first drug administration | |
Secondary | Presence of protein TLR5 in prostate biopsy and surgery samples | Using ELISA assay | Baseline to up to 45 days after the first drug administration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |